SG11202001861WA - Selective inhibitor of exon 18 and/or exon 21 mutant egfr - Google Patents
Selective inhibitor of exon 18 and/or exon 21 mutant egfrInfo
- Publication number
- SG11202001861WA SG11202001861WA SG11202001861WA SG11202001861WA SG11202001861WA SG 11202001861W A SG11202001861W A SG 11202001861WA SG 11202001861W A SG11202001861W A SG 11202001861WA SG 11202001861W A SG11202001861W A SG 11202001861WA SG 11202001861W A SG11202001861W A SG 11202001861WA
- Authority
- SG
- Singapore
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- egfr
- mutant
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 | ||
| PCT/JP2018/032314 WO2019045036A1 (ja) | 2017-09-01 | 2018-08-31 | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001861WA true SG11202001861WA (en) | 2020-04-29 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001861WA SG11202001861WA (en) | 2017-09-01 | 2018-08-31 | Selective inhibitor of exon 18 and/or exon 21 mutant egfr |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (de) |
| EP (1) | EP3677266B1 (de) |
| JP (1) | JP7065103B2 (de) |
| KR (1) | KR102676530B1 (de) |
| CN (2) | CN111465397B (de) |
| AU (1) | AU2018325819B2 (de) |
| BR (1) | BR112020004000A2 (de) |
| CA (2) | CA3224526A1 (de) |
| DK (1) | DK3677266T5 (de) |
| ES (1) | ES2972895T3 (de) |
| FI (1) | FI3677266T3 (de) |
| HU (1) | HUE066587T2 (de) |
| IL (1) | IL272929B2 (de) |
| JO (1) | JOP20200044A1 (de) |
| MX (1) | MX2020002296A (de) |
| PH (1) | PH12020500419A1 (de) |
| PL (1) | PL3677266T3 (de) |
| PT (1) | PT3677266T (de) |
| SG (1) | SG11202001861WA (de) |
| TW (1) | TWI838345B (de) |
| WO (1) | WO2019045036A1 (de) |
| ZA (1) | ZA202001445B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| TWI838345B (zh) | 2017-09-01 | 2024-04-11 | 日商大鵬藥品工業股份有限公司 | 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑 |
| KR20210110329A (ko) * | 2018-12-28 | 2021-09-07 | 다이호야쿠힌고교 가부시키가이샤 | L718 및/또는 l792 돌연변이 치료-내성 egfr 억제제 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| WO2006102079A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| PT1800675E (pt) | 2005-12-23 | 2011-08-30 | Nutricia Nv | COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA |
| BRPI1013999B1 (pt) | 2009-07-10 | 2020-06-02 | Taiho Pharmaceutical Co., Ltd. | Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| KR20140025327A (ko) | 2011-01-07 | 2014-03-04 | 다이호야쿠힌고교 가부시키가이샤 | 신규 2 고리형 화합물 또는 그 염 |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| EP2722332B1 (de) | 2012-02-23 | 2016-04-20 | Taiho Pharmaceutical Co., Ltd. | Chinolylpyrrolopyrimidylverbindung mit kondensiertem ring oder salz davon |
| WO2014129596A1 (ja) | 2013-02-22 | 2014-08-28 | 大鵬薬品工業株式会社 | 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物 |
| NO3037424T3 (de) | 2013-08-22 | 2018-04-07 | ||
| EP3143015B1 (de) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroarylverbindungen zur kinasehemmung |
| DK3157916T3 (en) | 2014-06-19 | 2019-03-18 | Ariad Pharma Inc | HETEROARYL COMPOUNDS FOR CHINESE INHIBITION |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| TWI838345B (zh) | 2017-09-01 | 2024-04-11 | 日商大鵬藥品工業股份有限公司 | 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑 |
-
2018
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 CA CA3224526A patent/CA3224526A1/en active Pending
- 2018-08-31 BR BR112020004000-2A patent/BR112020004000A2/pt unknown
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/de active Active
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active IP Right Grant
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja unknown
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272929A (en) | Selective inhibitor for EGFR mutant exon 18 and/or exon 21 | |
| IL266239A (en) | Selective inhibitor of egfr with exon 20 insertion mutation | |
| IL290399A (en) | kras g12c inhibitors and methods of using them | |
| IL272512A (en) | KRAS G12C inhibitors and methods of using them | |
| IL271025A (en) | Multibiotic substances and methods of using them | |
| EP3572400C0 (de) | Ezh2-inhibitor und verwendung davon | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| GB2583609B (en) | Cleanout tools and related methods of operation | |
| SG11202004318PA (en) | Acss2 inhibitors and methods of use thereof | |
| IL274045B1 (en) | Prodrugs of dantrolene and methods of using them | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL283782A (en) | Analosomes and methods of use | |
| EP3849664C0 (de) | Phenoxy-pyridyl-pyrimidinverbindungen und anwendungsverfahren | |
| IL286485A (en) | pi4-kinase inhibitors and methods of using them | |
| IL284330A (en) | Treatment-resistant EGFR inhibitor mutant L718 and/or L792 | |
| IL264977A (en) | Methods and preparations for the treatment of melanoma | |
| GB2589398B (en) | Compounds and methods of use | |
| KR102292781B9 (ko) | 폴리글리콜리드-폴리락티드 다중블록공중합체 수지 및 그 제조방법 | |
| EP3576745A4 (de) | Mittel zur hemmung von ngly1 und verfahren zur verwendung davon | |
| EP3849663C0 (de) | Pyrimidinyl-heteroaryloxy-naphthyl-verbindungen und anwendungsverfahren | |
| GB201908573D0 (en) | Compounds and methods of use |